Special Report on Cyclopharm (ASX:CYC): FDA approval is last piece of the puzzle

Marc Kennis Marc Kennis, March 1, 2022


Cyclopharm’s (ASX:CYC) core radiopharmaceutical product, Technegas, is used in functional lung ventilation imaging, particularly for the diagnosis of pulmonary embolism (PE). CYC is already selling in 60 countries around the world, but US FDA approval would open up the vast US market.


CYC is on of Marc & Stuart’s Top Picks. You can read the full report below!


Stocks Down Under Special Report on Cyclopharm - 1 March 2022



Stay up-to-date on ASX-listed Life Sciences stocks!

Make sure you subscribe to Stocks Down Under today




No credit card needed and the trial expires automatically.

Recent Posts

chinese students return to australia

As Chinese students return to Australia in 2023, which companies will derive the greatest benefit?

As Chinese students return to Australia, there are several companies that have been struggling in their absence and are set…

statutory results

Underlying v Statutory results? There’s a big difference between the 2 – here’s how to tell

When companies report results, you’ll hear underlying and statutory results. What is the difference between the two and how big…

macquarie group

If Macquarie Group is the ‘millionaires factory’ why has it retreated 15% in 12 months?

Macquarie Group (ASX:MQG) isn’t known as the ‘millionaire’s factory’ for nothing. Despite it being a relatively young bank compared to…